Catalog

Record Details

Catalog Search



Bad blood : secrets and lies in a Silicon Valley startup  Cover Image Book Book

Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.

Carreyrou, John, (author.).

Summary:

"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- Provided by publisher.

Record details

  • ISBN: 9781524731656
  • ISBN: 152473165X
  • ISBN: 9780525431992
  • Physical Description: x, 339 pages ; 25 cm
  • Edition: First hardback edition.
  • Publisher: New York : Alfred A. Knopf, 2018.

Content descriptions

General Note:
Publisher, publishing date and paging may vary.
Bibliography, etc. Note:
Includes bibliographical references (pages 305-324) and index.
Subject: Theranos (Firm) > History.
Hematologic equipment industry > United States.
Fraud > United States.

Available copies

  • 26 of 26 copies available at Missouri Evergreen. (Show)
  • 0 of 0 copies available at Livingston County.

Holds

  • 1 current hold with 26 total copies.
Show Only Available Copies
Location Call Number / Copy Notes Barcode Shelving Location Status Due Date

Loading Recommendations...

LDR 02679cam a22003858i 4500
0012869812
003ME
00520180718190230.0
008180316s2018 nyu e b 001 0 eng
010 . ‡a 2018000263
020 . ‡a9781524731656 ‡q(hardback)
020 . ‡a152473165X
020 . ‡a9780525431992 ‡q(paperback)
035 . ‡a(OCoLC)1029779381
040 . ‡beng ‡erda ‡dMTF
043 . ‡an-us---
049 . ‡aMZ7A
08200. ‡a338.7/681761 ‡223
1001 . ‡aCarreyrou, John, ‡eauthor. ‡0(ME)629368
24510. ‡aBad blood : ‡bsecrets and lies in a Silicon Valley startup / ‡cJohn Carreyrou.
250 . ‡aFirst hardback edition.
264 1. ‡aNew York : ‡bAlfred A. Knopf, ‡c2018.
300 . ‡ax, 339 pages ; ‡c25 cm
336 . ‡atext ‡btxt ‡2rdacontent
337 . ‡aunmediated ‡bn ‡2rdamedia
338 . ‡avolume ‡bnc ‡2rdacarrier
500 . ‡aPublisher, publishing date and paging may vary.
504 . ‡aIncludes bibliographical references (pages 305-324) and index.
520 . ‡a"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- ‡cProvided by publisher.
61020. ‡aTheranos (Firm) ‡xHistory.
650 0. ‡aHematologic equipment industry ‡zUnited States.
650 0. ‡aFraud ‡zUnited States. ‡0(ME)303567
904 . ‡aMARCIVE 2018
904 . ‡aMARCIVE 2022
901 . ‡a2869812 ‡b ‡c2869812 ‡tbiblio

Additional Resources